Endo to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

Endo, Inc. (OTCQX: NDOI), a diversified specialty pharmaceutical company, is set to report its fourth quarter and full year 2024 financial results on March 11, 2025. Investors and stakeholders eagerly await these results, as they will provide valuable insights into the company's financial performance and strategic direction. Here's a sneak peek into what we can expect from Endo's upcoming financial report.



Endo's acquisition of Endo International plc's assets in April 2024 has significantly impacted its financial performance. The company reported total revenues of $447 million in the combined second-quarter 2024, a decrease of 18% compared to $547 million in second-quarter 2023. This decrease was primarily attributable to decreased revenues from the Generic Pharmaceuticals and Sterile Injectables segments, partially offset by increased revenues from the Branded Pharmaceuticals segment.

Net Income in the combined second-quarter 2024 was $6,379 million compared to $23 million in second-quarter 2023. This change was primarily due to gains arising from the Plan's implementation and the application of fresh start accounting. Adjusted Net Income in the combined second-quarter 2024 was $105 million compared to $231 million in second-quarter 2023. This change was primarily due to decreased revenues.

Looking ahead to 2025, Endo is raising its 2024 full-year financial expectations and providing 2025 financial expectations, which represent a return to growth. The company's key achievements in 2024, aligned to its strategic pillars, include growing precision medicine, delivering late-stage therapeutics, building next-generation pipeline, and expanding global delivery infrastructure. These achievements position Endo for significant growth and evolution in 2025.

In conclusion, Endo's fourth quarter and full year 2024 financial results will provide valuable insights into the company's financial performance and strategic direction. With a strong focus on growth and innovation, Endo is well-positioned to capitalize on the growing demand for specialty pharmaceuticals and innovative therapies. Investors and stakeholders should closely monitor these results and the company's progress in executing its strategic initiatives.